ReNeuron Group (LON:RENE) released its earnings results on Friday. The company reported GBX (16.80) (($0.22)) earnings per share (EPS) for the quarter, Digital Look Earnings reports.
LON:RENE opened at GBX 54 ($0.71) on Friday. ReNeuron Group has a 12-month low of GBX 1.37 ($0.02) and a 12-month high of GBX 142.50 ($1.86).
In other news, insider Michael Hunt purchased 7,462 shares of the company’s stock in a transaction that occurred on Thursday, September 27th. The stock was bought at an average cost of GBX 67 ($0.88) per share, with a total value of £4,999.54 ($6,532.78).
ILLEGAL ACTIVITY WARNING: “ReNeuron Group (RENE) Posts Quarterly Earnings Results” was first posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://dakotafinancialnews.com/2018/12/16/reneuron-group-rene-posts-quarterly-earnings-results.html.
ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia.
Receive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with MarketBeat.com's FREE daily email newsletter.